Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.81 |
| ▸ | ITGAV | P06756 | 20/20 | 0.81 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7510058 | 0.96 | ITGB3 (0.81) | ITGB3ITGAVITGA2B | |
| SCHEMBL8325096 | 0.90 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| SCHEMBL7077079 | 0.88 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| SCHEMBL6944353 | 0.88 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| SCHEMBL7918275 | 0.88 | ITGB3 (0.92) | ITGB3ITGAVITGA2B | |
| SCHEMBL5165662 | 0.87 | ITGB3 (0.86) | ITGB3ITGAVITGA2B | |
| SCHEMBL5972719 | 0.86 | ITGB3 (0.85) | ITGB3ITGAVITGA2B | |
| SCHEMBL7367456 | 0.86 | ITGB3 (0.65) | ITGB3ITGAVITGA2B | |
| SCHEMBL6130318 | 0.85 | ITGB3 (0.84) | ITGB3ITGAVITGA2B | |
| SCHEMBL7509393 | 0.85 | ITGB3 (0.85) | ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020055499-A1 | Integrin receptor antagonists | HEERDING DIRK (US) | 2002-05-09 | — | — | US | disclosed |
| EP-1007051-A4 | INTEGRIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2001-08-29 | — | — | EP | disclosed |
| EP-1007051-A1 | INTEGRIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999006049-A1 | INTEGRIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055499-A1 | Integrin receptor antagonists | ITGB1, ITGB2, ITGA1 | ITGB3 8/4885ITGAV 14/4885ITGA2B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.